Cameron D. Thomas
YOU?
Author Swipe
View article: Impact of Race on Profiles of Platelet Reactivity and Clinical Outcomes in Clopidogrel‐Treated Participants
Impact of Race on Profiles of Platelet Reactivity and Clinical Outcomes in Clopidogrel‐Treated Participants Open
Black individuals undergoing percutaneous coronary intervention (PCI) experience higher rates of major adverse cardiovascular events (MACE) than non‐Black individuals. This study assessed the racial differences in platelet reactivity and c…
View article: <i>CYP2C19</i> Phenotype, P2Y <sub>12</sub> Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel Therapy
<i>CYP2C19</i> Phenotype, P2Y <sub>12</sub> Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel Therapy Open
Background Use of CYP2C19 genotyping to guide antiplatelet therapy is associated with improved clinical outcomes in patients naïve to P2Y 12 inhibitors undergoing percutaneous coronary intervention. The relationship between CYP2C19 genotyp…
View article: Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision <scp>PCI</scp>) Registry – Informing optimal antiplatelet strategies
Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision <span>PCI</span>) Registry – Informing optimal antiplatelet strategies Open
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y 12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) is indicated after percutaneous coronary intervention (PCI) to reduce the risk of atherothrombotic events. Approximately …
View article: Evaluating the Effect of Estimating Renal Function With the CKD‐EPI 2021 Equation on the ABCD‐GENE Score for Clopidogrel Response Prediction
Evaluating the Effect of Estimating Renal Function With the CKD‐EPI 2021 Equation on the ABCD‐GENE Score for Clopidogrel Response Prediction Open
The ABCD‐GENE score was developed to predict poor response to clopidogrel and includes A ge, B ody mass index, C hronic kidney disease (CKD; estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m 2 ), D iabetes, and CYP2C19 GENE va…
View article: Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for <i>CYP2D6</i>, <i>ADRB1</i>, <i>ADRB2</i>, <i>ADRA2C</i>, <i>GRK4</i>, and <i>GRK5</i> Genotypes and Beta‐Blocker Therapy
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for <i>CYP2D6</i>, <i>ADRB1</i>, <i>ADRB2</i>, <i>ADRA2C</i>, <i>GRK4</i>, and <i>GRK5</i> Genotypes and Beta‐Blocker Therapy Open
Beta‐blockers are widely used medications for a variety of indications, including heart failure, myocardial infarction, cardiac arrhythmias, and hypertension. Genetic variability in pharmacokinetic (e.g., CYP2D6 ) and pharmacodynamic (e.g.…
View article: <i>CYP2C19</i> Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention
<i>CYP2C19</i> Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention Open
Background Cytochrome P450 2C19 (CYP2C19) intermediate and poor metabolizer patients exhibit diminished clopidogrel clinical effectiveness after percutaneous coronary intervention (PCI). However, outcome studies to date have lacked racial …
View article: Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US
Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US Open
Importance A platelet ADP P2Y12 receptor (P2Y12) inhibitor plus aspirin is standard therapy for patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Compared with clopidogrel, prasugrel and ticagr…
View article: Pharmacogenetics of <scp> P2Y <sub>12</sub> </scp> receptor inhibitors
Pharmacogenetics of <span> P2Y <sub>12</sub> </span> receptor inhibitors Open
Oral P2Y 12 inhibitors are commonly prescribed for cardiovascular disease and include clopidogrel, prasugrel, and ticagrelor. Each of these drugs has its strengths and weaknesses. Prasugrel and ticagrelor are more potent inhibitors of plat…
View article: Evaluation of Potential Racial Disparities in<i>CYP2C19</i>‐Guided P2Y<sub>12</sub>Inhibitor Prescribing After Percutaneous Coronary Intervention
Evaluation of Potential Racial Disparities in<i>CYP2C19</i>‐Guided P2Y<sub>12</sub>Inhibitor Prescribing After Percutaneous Coronary Intervention Open
Black patients suffer worse outcomes after percutaneous coronary intervention (PCI) than White patients. Inequities in antiplatelet prescribing may contribute to this health disparity. We compared P2Y 12 inhibitor prescribing by race follo…
View article: Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the <scp>IGNITE ADOPT PGx</scp> investigators
Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the <span>IGNITE ADOPT PGx</span> investigators Open
Opioid prescribing for postoperative pain management is challenging because of inter‐patient variability in opioid response and concern about opioid addiction. Tramadol, hydrocodone, and codeine depend on the cytochrome P450 2D6 (CYP2D6) e…
View article: Impact of the ABCD‐GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi‐Site, Real‐World Investigation
Impact of the ABCD‐GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi‐Site, Real‐World Investigation Open
The A ge, B ody mass index, C hronic kidney disease, D iabetes mellitus, and CYP2C19 GENE tic variants (ABCD‐GENE) score was developed to identify patients at risk for diminished antiplatelet effects with clopidogrel after percutaneous cor…
View article: How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial
How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial Open
CYP2D6 genotype is increasingly being integrated into practice to guide prescribing of certain medications. The CYP2D6 drug metabolizing enzyme is susceptible to inhibition by concomitant drugs, which can lead to a clinical phenotype that …
View article: Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across <i>CYP2D6</i> Genotype‐Derived Activity Scores
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across <i>CYP2D6</i> Genotype‐Derived Activity Scores Open
Recent CYP2D6 phenotype standardization efforts by CYP2D6 activity score (AS) are based on limited pharmacokinetic (PK) and pharmacodynamic (PD) data. Using data from two independent clinical trials of metoprolol, we compared metoprolol PK…
View article: Impact of the <i>CYP2C19*17</i> Allele on Outcomes in Patients Receiving Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
Impact of the <i>CYP2C19*17</i> Allele on Outcomes in Patients Receiving Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention Open
Genotyping for CYP2C19 no function alleles to guide antiplatelet therapy after percutaneous coronary intervention (PCI) improves clinical outcomes. Although results for the increased function CYP2C19*17 allele are also reported, its clinic…
View article: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2C19</i> and Proton Pump Inhibitor Dosing
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2C19</i> and Proton Pump Inhibitor Dosing Open
Proton pump inhibitors (PPIs) are widely used for acid suppression in the treatment and prevention of many conditions, including gastroesophageal reflux disease, gastric and duodenal ulcers, erosive esophagitis, Helicobacter pylori infecti…
View article: Pharmacogenetic factors affecting β-blocker metabolism and response
Pharmacogenetic factors affecting β-blocker metabolism and response Open
Substantial data suggest that specific ADRB1 and GRK5 genotypes are associated with improved β-blocker efficacy and have potential for use to guide therapy decisions in the clinical setting. While the data do not justify ordering a CYP2D6 …
View article: Evaluation of the protective effects of β-blockers in the management of acute exacerbations of chronic obstructive pulmonary disease
Evaluation of the protective effects of β-blockers in the management of acute exacerbations of chronic obstructive pulmonary disease Open
β-blocker therapy could result in a paradigm shift in managing chronic obstructive pulmonary disease patients from a true cardiopulmonary approach. This retrospective cohort study demonstrated early β-blocker continuation in patients admit…